The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
The capital bill also stipulates the creation of an apprenticeship program in the construction industry to provide part of the labor force necessary. Transportation spending includes money for mass transit and pedestrian paths, with hundreds of millions going to projects involving Chicago. Some major projects are the reconstruction and capacity enhancement of the Kennedy Expressway ($561 million), expanding a train service between Chicago and Rockford ($275 million), and upgrades for the Pace suburban bus service ($220 million). Millions of dollars will be spent on improving the Chicago–St. Louis higher-speed railway, and moving passenger and rail traffic in Springfield to one set of tracks, eliminating a physical barrier. As justification for the multi-billion-dollar spending bill and the accompanying tax hikes, Pritzker said that Illinois had not had a major infrastructure plan for two decades and asserted that improved infrastructure would help drivers on repairs. By 2026, the Rebuild Illinois program had administered $25.6 billion in roadway investments, financing the improvement or expansion of 9,058 route-miles—and over 24,000 lane-miles—of highway and roads, more than 900 bridges, and 1,475 other safety improvements, from routine maintenance projects and minor resurfacings to extensive interstate and bridge reconstructions.
== Diagnosis == While Sjögren's disease is one of the most common autoimmune diseases, it has no specific and non-invasive diagnostic tests. Diagnosing Sjögren's disease is complicated by the range of symptoms that a patient may manifest, and the similarity between symptoms of Sjögren's disease and those of other conditions. Also, patients with Sjögren’s symptoms approach different specialities for treatment, which can make diagnosis difficult. Since dry eyes and dry mouth are very common symptoms, and frequently occur in people over 40, affected people may believe the symptoms are age-related. Therefore, they often ignore them. Some medications can cause symptoms similar to those of Sjögren's disease.
The fact that the prostate was one and not two organs was an idea popularised throughout the early 18th century, as was the English language term used to describe the organ, prostate, attributed to William Cheselden. A monograph, "Practical observations on the treatment of the diseases of the prostate gland" by Everard Home in 1811, was important in the history of the prostate by describing and naming anatomical parts of the prostate, including the median lobe. The idea of the five lobes of the prostate was popularized following anatomical studies conducted by American urologist Oswald Lowsley in 1912. John E. McNeal first proposed the idea of "zones" in 1968; McNeal found that the relatively homogeneous cut surface of an adult prostate in no way resembled "lobes" and thus led to the description of "zones". Prostate cancer was first described in a speech to the Medical and Chiurgical Society of London in 1853 by surgeon John Adams and increasingly described by the late 19th century. Prostate cancer was initially considered a rare disease, probably because of shorter life expectancies and poorer detection methods in the 19th century. The first treatments of prostate cancer were surgeries to relieve urinary obstruction. Samuel David Gross has been credited with the first mention of a prostatectomy, as "too absurd to be seriously entertained" The first removal for prostate cancer (radical perineal prostatectomy) was first performed in 1904 by Hugh H. Young at Johns Hopkins Hospital; partial removal of the gland was conducted by Theodore Billroth in 1867.
Sources: en.wikipedia.org
The National Dope Testing Laboratory (NDTL) is a premier analytical testing & research organization established as an autonomous body under the Ministry of Youth Affairs and Sports, Government of India. It is the only laboratory in the country responsible for human sports dope testing. It is headed by Chief Executive Officer (CEO). Dr. Puran Lal Sahu is the Scientific Director of NDTL. It is accredited by National Accreditation Board for Testing & Calibration Laboratories, NABL (ISO/IEC 17025:2017) for human dope testing of urine & blood samples from human sports. NDTL is one of the 29 WADA accredited laboratories Archived 2021-04-18 at the Wayback Machine in the world. It is one of the modern and state-of-the-art laboratories in the country equipped with the latest analytical instrumentation.
=== The Lancet COVID-19 Commission task force === In November 2020, Richard Horton, editor of The Lancet, appointed economist Jeffrey Sachs as chair of its COVID-19 Commission, with wide-ranging goals relating to the virus and pandemic. Sachs set up a number of task forces, including one on the origins of the virus. Sachs appointed Peter Daszak, a colleague of Sachs' at Columbia, to head this task force, two weeks after the Trump administration prematurely ended a federal grant supporting a project led by Daszak, EcoHealth Alliance, which worked with the Wuhan Institute of Virology. This appointment was criticised as creating a conflict of interest, for instance by Richard Ebright, chemical biologist at Rutgers University, who called the commission an "entirely Potemkin commission" in the National Review. Daszak stated that the task force was formed to "conduct a thorough and rigorous investigation into the origins and early spread of SARS-CoV-2". The task force has twelve members with backgrounds in One Health, outbreak investigation, virology, lab biosecurity and disease ecology. The task force planned to analyse scientific findings and did not plan to visit China. However, as Sachs became increasingly drawn to the lab leak theory, he came into conflict with Daszak and his task force. In June 2021, The Lancet announced that Daszak had recused himself from the commission. On 25 September 2021, the task force work was folded after procedural concerns and a need to broaden its scope to examine transparency and government regulation of risky laboratory research.
=== Other potential applications === As a highly scattering material for ultra-white coatings Activate the dissolution of cellulose in different solvents Regenerated cellulose products, such as fibers films, cellulose derivatives Tobacco filter additive Organometallic modified nanocellulose in battery separators Reinforcement of conductive materials Loud-speaker membranes High-flux membranes Computer components Capacitors Lightweight body armour and ballistic glass Corrosion inhibitors Radio lenses Art Conservation
Assessing the Cardinals' pennant chances during 1957 spring training, manager Fred Hutchinson said, "We've got at least three pitchers capable of winning 20-Herm Wehmeier, Sam Jones, and Vinegar Bend Mizell. If a couple of them can do it, we'll make plenty of trouble." Mizell's fastball had slowed a bit in 1956, and it was even slower in 1957. He was giving up more home runs than he had before he joined the Army, and the Cardinals were worried about his weight and his windup motion. Mizell spent much of the early part of the season in the bullpen, and the Cardinals even attempted to send him to Houston, but they were unable to get him through waivers. They had him watch films of his pitching, not common practice at the time, to help him correct his mistakes. On July 18, he relieved Hoyt Wilhelm in the ninth inning with the Cardinals leading the Dodgers 9–4 and the bases loaded. He retired Duke Snider on a groundout but then walked Gino Cimoli to bring up Gil Hodges, a right-handed hitter. Though many managers would have inserted a right-hander in this situation, Hutchinson left Mizell in to face him, and Hodges hit a grand slam, tying the game, which the Cardinals eventually lost 10–9. The decision drew ire from St. Louis fans, and general manager Frank Lane and executive vice president Richard A.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.